Critical Comparison: Fate Therapeutics (NASDAQ:FATE) vs. Geron (NASDAQ:GERN)

Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Geron (NASDAQ:GERN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Profitability

This table compares Fate Therapeutics and Geron’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fate Therapeutics -1,941.09% -73.92% -45.16%
Geron -23.04% -16.29% -6.82%

Risk and Volatility

Fate Therapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Insider and Institutional Ownership

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Fate Therapeutics and Geron, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics 1 1 4 0 2.50
Geron 1 2 3 0 2.33

Fate Therapeutics currently has a consensus target price of $5.80, suggesting a potential upside of 408.77%. Geron has a consensus target price of $3.75, suggesting a potential upside of 298.13%. Given Fate Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than Geron.

Earnings and Valuation

This table compares Fate Therapeutics and Geron”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fate Therapeutics $4.75 million 29.18 -$136.32 million ($1.03) -1.11
Geron $183.88 million 3.30 -$83.50 million ($0.08) -11.77

Geron has higher revenue and earnings than Fate Therapeutics. Geron is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Fate Therapeutics beats Geron on 8 of the 14 factors compared between the two stocks.

About Fate Therapeutics

(Get Free Report)

Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.

About Geron

(Get Free Report)

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.